ENG and urothelial carcinoma: Recently, a chimeric monoclonal antibody (TRC105) targeting ENG has entered clinical trial to treat patients with advanced urothelial carcinoma [53], indicating that ENG may be a promising anti-angiogenic target of cancer therapy.